L1-1664 - Safety Profile of Tedizolid Phosphate Compared to Linezolid in a Phase 3 ABSSSI Study (PDF 272KB)

A-1295a - Lack of MAO Inhibition by Tedizolid Phosphate in Clinical and Nonclinical Studies (PDF 313KB)

E-1479 - In Vitro Activity Profile of Tedizolid (TZD) and Correlations with Linezolid (LZD) Activity Against Recent Staphylococcal Isolates (PDF 255KB)

A-1293 - Safety and Pharmacokinetics of Single Oral Administration of Tedizolid Phosphate in Healthy Elderly Subjects and Adult Control Subjects (PDF 315KB)

A-1294 - A Phase 1 Study of Intravenously Administered Tedizolid Phosphate in Subjects with Advanced Renal Impairment (PDF 306KB)

A-1295 - A Phase 1 Study of Orally Administered Tedizolid Phosphate in Subjects with Moderate or Severe Hepatic Impairment (PDF 337KB)

A-1292 - Safety and Pharmacokinetics after Single Oral and IV Administration of Tedizolid Phosphate in Adolescent Patients (PDF 347KB)

A-1291 - Study of the Cellular Uptake and Subcellular Distribution of the Oxazolidinone Tedizolid (TZD) in Murine J774 Macrophages: Lack of Association with Mitochondria (PDF 246KB)

E-778 - Comparison of Tedizolid (TZD) In Vitro Activity with that of Other Key Gram-Positive Agents Against Recent Enterococcal and Streptococcal Isolates (PDF 360KB)

C2-142 - In Vitro Activity of Tedizolid and Radezolid against Linezolid-Resistant Gram-positive Clinical Isolates with Genetically Characterized Resistance Mechanisms
(PDF 4MB)

F-2018 - Antibacterial Agents Targeting DNA Gyrase B and Topoisomerase IV: Optimization of Gram-Negative Antibacterial Activity and Drug Properties (PDF 625KB)

F-2019 - Potent Actvity of Novel Gyrase/Topoisomerase Inhibitors Against Gram-Negative and Gram-Positive Pathogens with Important Resistance Phenotypes (PDF 853KB)

F-2020 - Microbiological Profile of Novel Inhibitors of DNA Gyrase and Topoisomerase IV Against Gram-Negative Pathogens (PDF 980KB)

F-2021 - In vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosa (PDF 504KB)

F-2022 - Antimicrobial Activity and in vivo Efficacy of Novel GyrB/ParE Inhibitors versus Burkholderia pseudomallei (PDF 1.2MB)

F-2023 - Broad Spectrum Activity of Novel, Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV Against Biodefense Pathogens (PDF 769KB)

F-2024 - Advanced Microbiological Profile of New DNA Gyrase/Topoisomerase IV Inhibitors (PDF 648KB)

F-2025 - Selection and Characterization of E. coli Mutants with Reduced Susceptibility to Novel DNA Gyrase/Topoisomerase IV Inhibitors (PDF 376KB)

F-2026 - Comparative Pharmacokinetics Of Novel Inhibitors Of DNA Gyrase/Topoisomerase IV (PDF 445KB)

F-2027 - Use of Microdosing and Accelerator Mass Spectrometry to Evaluate the Pharmacokinetics of a Novel GyrB/ParE Inhibitor (PDF 11.1MB)

F-2028 - Activity of Novel, Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV in Murine Infection Models (PDF 361KB)

F-2029 - In vitro Activity and Pharmacodynamic Evaluation of Dual Targeting Inhibitors (DTI) of Bacterial DNA Gyrase and Topoisomerase IV against Extracellular and Intracellular Forms of Ciprofloxacin-susceptible (CIP^S) and Ciprofloxacin-resistant (CIP^R) Pseudomonas aeruginosa and Staphylococcus aureus (PDF 844KB)

L1-1496 - Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Dose-Ranging Phase 2 Tedizolid Phosphate (TR-701) Study: Assessment of Efficacy with New FDA Guidance (PDF 287 KB)

E-1324- Comparative Potency of Oxazolidinones Tedizolid (TR-700) and Linezolid Against Target Gram-Positive Pathogens in the US from 2009-2010 (PDF 372 KB)

E-1342 - Activity of Tedizolid (TR-700) Against Well-characterized MRSA Strains of Diverse Epidemiological Origin (PDF 92 KB)

A1-1746 - Pharmacokinetics and Pulmonary Disposition of Tedizolid and Linezolid in Three Murine Models (PDF 264 KB)

A1-1747- Pulmonary Disposition of Tedizolid Following 200mg Once-Daily Oral Tedizolid Phosphate in Healthy Volunteers (PDF 252 KB)

F1-1837 - The Discovery of Potent, Dual Targeting Pyrrolopyrimidine Inhibitors of Bacterial DNA Gyrase B and Topoisomerase IV with Broad Spectrum Antibacterial Activity (PDF 28.2 MB)

F2-1872 - The Discovery of Novel, Dual Targeting Inhibitors of Bacterial DNA Gyrase B and Topoisomerase IV using Pharmacophore-Based Crystallographic Fragment Screening (PDF 29.9 MB)

C2-945 - In vitro activity of tedizolid (TR-700, formerly known as torezolid) against linezolid-resistant Gram-positive clinical isolates possessing the cfr methyltransferase gene and/or ribosomal gene mutations (PDF 280 KB)

B-709 - Anti-virulence Effect of TR-700 on MSSA and MRSA Strains Annie Causing Complicated Skin Soft Tissue Infections (cSSTIs) (PDF 637 KB)

F1-1834 - Structure-based Design of Novel Antibacterial Agents Targeting DHFR (PDF 277 KB)

F1-835 - Structure-Based Design of New DHFR-based Antibacterial Agents (Part 1): 7-Aryl-2,4-diaminoquinazolines SAR (PDF 356 KB)

F1-836 - Structure-Based Design of New DHFR-based Antibacterial Agents (Part 2): 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines SAR (PDF 356 KB)

F1-837 - Microbiological Profile of Novel 2,4-Diaminoquinazoline DHFR Inhibitors (PDF 356 KB)

F1-838 - Advanced Microbiology and in vivo Efficacy of Rx101005, a Novel 2,4-diaminoquinazoline DHFR Inhibitor (PDF 356 KB)

F1-855 -Evaluation of Novel 2,4-Diaminoquinazoline Inhibitors of Candida albicans DHFR (PDF 356 KB)

C1-1426 -Evidence for Multiple Functionality of Campylobacter jejuni DNA Gyrase in Chromosomal Replication (PDF 356 KB)

C1-1431 - Elevated Linezolid Resistance in Clinical S. aureus cfr Isolates is Associated with Co-occurring Mutations in Ribosomal Protein L3 (PDF 356 KB)

C1-1432 - Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant S. aureus Strains Possesing the cfr Methyltransferase Gene or Ribosomal Mutations (PDF 356 KB)

P-1591 - Rationale for the Selection of a 200mg Therapeutic Dose of Oral Torezolid Phosphate for Complicated Skin Infections (PDF 637 KB)

P-1592 - Microbiological Efficacy of Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections (PDF 277 KB)

P-1593 - Absolute Oral Bioavailability and Intravenous Pharmacokinetics of Torezolid Phosphate in Healthy Subjects (PDF 356 KB)

P-1594 - Improved Pharmacokinetics of the Novel Oxazolidinone Antibiotic Torezolid Phosphate Compared to Linezolid in Healthy Subjects (PDF 356 KB)

A1-1934 - Torezolid (TR-700), a novel methyltetrazolyl-oxazolidinone, accumulates markedly within human THP-1 macrophages and shows activity towards intraphagocytic Legionella pneumophila: comparison with linezolid (PDF 1.4MB)

A1-1935 - Defining the Impact of Granulocytes (G) on the Kill of Methicillin-Resistant Staphylococcus aureus (MRSA) by the New Oxazolidinone Prodrug Torezolid (PDF 564 KB)

A1-1939 - Comparative Pharmacodynamics of a Novel Oxazolidinone, Torezolid Phosphate (Torezolid), Against S. aureus in a Neutropenic Murine Pneumonia Infection Model (PDF 224 KB)

A1-1947 - Evaluation of Tissue Distribution of TR-700 in Healthy Volunteers, Using Microdialysis (PDF 552 KB)

C1-1346 - An Unexpectedly Low Cost of Fitness Associated with Acquisition of the cfr Resistance Gene (PDF 180 KB)

C1-1349 - Mutations in Ribosomal Protein L3 are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin (PDF 1MB)

C1-1364a - In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial (PDF 764 KB)

C1-1364b - Genetic Environment and Instability of cfr in MRSA CM05 (PDF 308 KB)

E-807 - Comparative Activity of TR-700 Against Staphylococci Blood Isolates Collected in Spain (PDF 180 KB)

E-808 - Activity of torezolid (TR-700) against linezolid-resistant MRSA strains with cfr gene mediated resistance (PDF 484 KB)

E-809 - In Vitro Activity of Torezolid (TR-700) versus Linezolid against Chlamydia species (PDF 424 KB)

P-1103 - Characterization of Resistance Following Serial Passage of Staphylococcus aureus in the Presence of the Novel Oxazolidinone Torezolid (TR-700) and Linezolid (PDF 456 KB)

P-1104 - Characterization of the Novel Oxazolidinone Torezolid (TR-700) and Linezolid Spontaneous Mutation Frequencies and Resistance Mechanisms in Staphylococcus aureus (PDF 457 KB)

P-1091 - Effect of Food on the Pharmacokinetics of Torezolid (TR-700) in Healthy Adult Subjects (PDF 387 KB)

A-985 - Pharmacodynamics of Torezolid in a Mouse Thigh Infection Model Against Staphylococcus aureus MRSA Strain ATCC33591. (PDF 588 KB)

F1-334 - Discovery and SAR of a Novel Series of PyrimidineAntibacterialsTargeting Methionyl-tRNASynthetase. (PDF 552 KB)

F1-335 - In Vitro Activity of RX100472 Againts Clinically Important Bacteria (PDF 124 KB)

F1-336 - Advanced Microbiology Study of RX100472, A Novel Methionyl tRNA Synthetase (MetRS) Inhibitor (PDF 204 KB)

F1-337 - In Vivo Efficacy of RX100472, A Novel Methionyl tRNA Synthetase (metRS) Inhibitor (PDF 156 KB)

F1-2060 - MICs of TR-700 – the Active Moiety of the Novel Oxazolidinone Prodrug Torezolid – for Linezolid-Susceptible and -Resistant Enterococci and Staphylococci (PDF 372 KB)

F1-2061 - TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-positive Species with Well-Characterized Resistance Mechanisms (PDF 180 KB)

F1-2062 - In-Vitro Pharmacodynamics of TR-700, the Active Moiety of Prodrug Torezolid, A Novel Oxazolidinone, in a Kill-Curve Model (PDF 188 KB)

F1-2065 - In Vitro and In Vivo Efficacy of TR-700 and Torezolid Versus the Linezolid-and-Methicillin-Resistant Staphylococcus Aureus CFR Strain CM05 (PDF 380 KB)

F1-2066 - Demonstration of Torezolid Efficacy in a Mouse Inhalation Anthrax Model (PDF 92 KB)

F1-2067 - Absence of a Pressor Response to Oral Tyramine in Conscious Telemeterized Rats Treated with the Novel Oxazolidinone Torezolid: Comparison to Linezolid (PDF 344 KB)

F1-2068 - Quality Control Parameters for TR-700 Broth
Microdilution Susceptibility Tests (PDF 100 KB)

F1-2069 - Relative Potency of TR-700, the Active Moiety of Prodrug Torezolid Against Selected Bacterial Pathogens and Provisional Disk Test Criteria (PDF 152 KB)

F1-2069a - Hematological Effects of Torezolid, Linezolid and Placebo Administered for 21 Days in Healthy Subjects (PDF 156 KB)

F1-2070 - Structure-Guided Design of Pyrimidine Antibacterials Targeting Methionyl-tRNA Synthetase (MetRS) (PDF 244 KB)

Structure-Activity Relationship of Substituted Pyridyl Phenyl Oxazolidinone Derivatives, Including TR-700 (DA-7157). (PDF 84 KB)

Single and Repeated-dose Toxicity of Torezolid (DA-7218) in Rodents.(PDF 140 KB)

Pharmacokinetics of Torezolid (DA-7218), a New Oxazolidinone in Mice, Rats, and Dogs. (PDF 132 KB)

In vitro and In vivo Antibacterial Activity of Torezolid (DA-7218) against Penicillin-resistant Streptococcus pneumoniae. (PDF 128 KB)

The New Oxazolidinone, TR-700 (DA-7157): Effects of pH, Inoculum, Serum and Media on Antibacterial Activity. (PDF 144 KB)

The In Vitro Activity of TR-700, the Active Ingredient of the Prodrug Torezolid, a Novel Oxazolidinone Antibacterial Agent.(PDF 100 KB)

Selection of Optimal Antisense Clones of Bacillus anthracis for Drug Discovery Efforts V. (PDF 140 KB)

Specific Synergistic Effect of Mur Pathway Antisense Clones of Bacillus anthracis Against β-Lactams. (PDF 180 KB)

Identification of Novel Inhibitors of Methionyl-tRNA Synthetase by Virtual Screening (PDF 152 KB)

ASM Biodefense Poster (PDF 263kb)